Prostate Cancer | Topics

Experts Attribute Higher Incidence of Metastatic Prostate Cancer in the US to Fewer PSA Screenings
February 15, 2021

More cases of metastatic prostate cancer may be linked with a reduction in prostate-specific antigen screening, experts say.

PSMA PET Imaging Agent 18F-DCFPyL Enables Better Detection of Localized Metastatic Lesions
February 14, 2021

Findings from the phase 3 CONDOR trial support the use of the PSMA PET imaging agent 18F-DCFPyL as the FDA prepares to make a decision on a new drug application regarding its use.

Survival Advantage Is Experienced by Patients Receiving Apalutamide Added to ADT for mCSPC
February 13, 2021

Compared with androgen-deprivation therapy alone, patients with metastatic castration-sensitive prostate cancer had better outcomes when apalutamide was added to systemic therapy.